Drug news
Adventrx Pharma discontinues Exelbine for Non Small Cell Lung Cancer
Meetings between Adventrx Pharma and the FDA were not productive regarding the FDA Complete Response Letter and Adventrx has decided to focus its capital on its other compounds, ANX-188 and ANX-514, which reflect larger market opportunities. The company will discontinue its Exelbine programme until it finds a partner or outside investor.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.